- ABVC BioPharma Inc (NASDAQ:ABVC) shares gained during the market trading session on continued momentum from yesterday’s dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research.
- Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms.
- In addition, BioKey has entered into a three-year distribution agreement with Define Biotech Co Ltd, Taiwan-based pharmaceutical marketing.
- Zacks Small-Cap Research analyst M. Marin highlighted the company’s two lead candidates, ABV-1505 and Vitargus (ABV-1701).
- ABV-1505 is in Phase 2 for adult attention-deficit/hyperactivity disorder. Zacks values the ABVC stock at $9.50.
- In 2022, ABVC is planning to begin a self-funded pivotal trial for Vitargus for retinal detachment vitreous hemorrhage.
- Price Action: ABVC shares gained almost 20% at $4.08 before pulling back at $3.53, +6.68% during the market session on the last check Friday.
Jianzhi Education Technology Group Company Enters Into Strategic Cooperation Agreement With Jinqiao Management Bureau Of Shanghai Pilot Free Trade Zone On Vocational Training Online Platform
Jianzhi Education Technology Group Company Limited (the "Company" or "Jianzhi") (NASDAQ:JZ), a leading provider of digital educational content in China, today announced that the Company's
